RadMD First to Offer CME-Certified Education and Training For Medical Imaging in Clinical Trials
BRITI Accredited Courses Designed to Improve Quality and Accuracy of Results
DOYLESTOWN, Pa., July 28 /PRNewswire/ -- RadMD LLC (www.rad-md.net) has become the first company to offer a broad range of accredited CME courses in the area of medical imaging for pharmaceutical, medical device and biotech clinical trials.
The comprehensive education and training is offered through the company's Blinded Reader and Investigator Training Institute (BRITI)(TM). RadMD is partnering with International Center for Postgraduate Medical Education (ICPME) to obtain the CME certification.
"A huge number of clinical trials use medical imaging to demonstrate effectiveness," said Lisa Schleelein, MEd, ICPME's director of CME. "The primary goal of CME activities is to improve practice performance and patient care. RadMD is contributing to the overall quality of this process with educational activities that improve the utilization, acquisition and interpretation of medical images."
Founded by medical imaging experts Kohkan Shamsi, MD, PhD, and Richard Patt, MD, RadMD will offer both CME-certified and non-CME course modules providing clinical trial personnel with formalized training and testing on a variety of topics related to the use of medical imaging in clinical trials. The curricula were developed to reduce bias, increase data reliability and improve the accuracy of the results.
"The FDA emphasizes the role of training trial personnel but there are no standards in place to govern the use of medical imaging for this purpose," said Dr. Richard Patt, co-founder of RadMD. "Other companies in our industry use education as a marketing tool to sell their services; we recognize the crucial importance of independent, peer-reviewed validation for education and training."
The BRITI training program will offer both introductory and advanced courses on the use of medical imaging in trials, including specific evaluation methods. Customized modules for specific trials can also be developed to train pharmaceutical personnel, on-site investigators and blinded readers.